Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI-2001 in Relapsed or Refractory CD19+ B-cell Lymphoma, CLL, and SLL
NCT05963217Phase 1Recruiting
- Sponsor
- University Health Network
- Start
- Jul 2023
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TBI-2001 in B cell lymphoma, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by University Health Network. Primary endpoints: Safety of TBI-2001 at 1 year and Recommended phase 2 dose of TBI-2001 at 1 year. Started Jul 2023; status: recruiting.
02
Drugs
TBI-2001
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05963217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963217.